Quantcast
Last updated on April 25, 2014 at 5:25 EDT
Single Cell Type Found To Cause Most Invasive Bladder

Single Cell Type Found To Cause Most Invasive Bladder Cancers: Study

Lawrence LeBlond for redOrbit.com - Your Universe Online Invasive bladder cancer (IBC), a malignant disease that currently affects more than 375,000 people worldwide, has been found to be caused by a single type of cell in the lining of the...

Latest Hedgehog signaling pathway Stories

2014-01-08 12:28:08

Presentation to be held at Monday, January 13, 2014 at 10:00 a.m. Pacific Time at the Parc 55 Wyndam in Union Square, San Francisco TAMPA, Fla. and SAN DIEGO, Jan. 8, 2014 /PRNewswire/ -- HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that its president and chief executive officer, Mr. Nicholas J. Virca, will present at the...

Mouse Study Offers Hope For Potential Down Syndrome Treatment
2013-09-05 06:07:35

April Flowers for redOrbit.com - Your Universe Online A new compound that dramatically bolsters learning and memory when given on the day of birth to mice with a Down syndrome-like condition has been identified by researchers from Johns Hopkins and the National Institutes of Health (NIH). The findings, published in Science Translational Medicine, shows that the single-dose treatment seems to enable the cerebellum of the rodent’s brains to grow to a normal size. The compound is a small...

2012-06-19 22:07:38

Combining a new targeted therapy with standard chemotherapy may help defeat pancreatic cancer, according to results presented at the American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges conference, held here June 18-21. "We believe that GDC-0449 has the potential to change the approach to treating pancreatic cancer," said Edward J. Kim, M.D., Ph.D., a medical oncologist at the University of Michigan Comprehensive Cancer Center in Ann Arbor, Mich....

2012-04-03 09:09:25

Johns Hopkins investigators are testing a way to use drugs that target a cholesterol pathway to enhance the cancer-killing potential of standard chemotherapy drugs. Their tests, in mouse models of pancreatic cancer, may yield new and more effective combinations of current and possibly new anti-cancer drugs. Besides their deadly consequences, pancreatic cancer and heart disease share a connection with genetic pathways that control cholesterol and a cell signaling system known as the...

2012-04-02 21:07:54

Brown University biologists have found a new molecule in fruit flies that is key to the information exchange needed to build wings properly. They have also uncovered evidence that an analogous protein may exist in people and may be associated with problems such as cleft lip, or premature ovarian failure. As they work together to form body parts, cells in developing organisms communicate like workers at a construction site. The discovery of a new signaling molecule in flies by Brown...

2012-03-20 11:19:01

Hedgehog and mTOR converge; Findings suggest new combination therapy Identification of a non-traditional pathway for spiriting a cancer-promoting protein into the cell nucleus points to a possible combination therapy for esophageal cancer and indicates a mechanism of resistance for new drugs that attack the Hedgehog pathway. A team of researchers at The University of Texas MD Anderson Cancer Center reports in the March 20 Cancer Cell that the mTOR molecular pathway promotes the activity...

2012-02-16 06:00:00

LAUSANNE, Switzerland and LEXINGTON, Massachusetts, February 16, 2012 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, and Debiopharm Group (Debiopharm), a group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that Debiopharm has begun treating patients in a Phase Ib clinical trial of Heat Shock Protein 90 (HSP90)...

2012-02-14 12:41:44

Researchers of the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch have now identified and described a molecular mechanism underlying the most common malformation of the brain in humans. In holoprosencephaly (HPE), the forebrain (prosencephalon) is only incompletely formed. Here a binding site (receptor) for cholesterol plays a key role. If this receptor is defective, specific signals cannot be received, and the forebrain cannot separate into two hemispheres, as...

2012-01-30 10:43:00

SILVER SPRING, Md., Jan. 30, 2012 /PRNewswire-USNewswire/ -- Today, Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body (metastatic). (Logo:...

2011-12-12 16:09:54

Baylor College of Medicine researchers presented new data regarding breast cancer stem cells, the unique subset of breast cancer cells that are capable of initiating tumor growth and are relatively resistant to chemo and radiotherapies, today at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. The conference is co-sponsored by BCM, the American Association of Cancer Research and the Cancer Therapy and Research Center at the University of Texas Health Science Center in San Antonio....